Vanderbilt University scientists have contributed to a major finding, reported this week in the journal Nature, which could lead to the first effective vaccine against respiratory syncytial virus (RSV), a significant cause of infant mortality.
Nine Vanderbilt University faculty members named to endowed chairs were honored for their academic achievements during a celebration Jan. 22 at the Student Life Center.
Vanderbilt research shows that human antibodies to the natural strain of H5N1 also protected against a dangerous lab-created airborne strain developed several years ago by scientists in the Netherlands and at the University of Wisconsin.
A worrisome new avian influenza virus, called H7N9, emerged this spring in Eastern China.
Vanderbilt vaccine researchers are using gold nanotechnology to develop a new approach to making vaccines.
Accessibility Tools